Comparing Raman Spectroscopy to Flow Cytometry for Detecting Leukemia
Official title: Raman Spectroscopy Compared to Flow Cytometry as a Method for Assessing Measurable Residual Disease in Patients With Acute Lymphoblastic Leukemia
Run by Hospital Regional de Alta Especialidad del Bajio · NCT06291428 · Data updated 2026-11-12
This study is testing if a new light-based method called Raman spectroscopy can better detect leftover leukemia cells in patients with acute lymphoblastic leukemia compared to the usual flow cytometry method.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years to 70 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Hospital Regional de Alta Especialidad del Bajio Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (León, Guanajuato) |
| Status | Recruiting |
| Started | October 15, 2024 |
| Main results expected | December 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | March 12, 2025 |
| Trial ID | NCT06291428 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with acute lymphoblastic leukemia who require MRD determination.
✕Probably not a fit
Patients who do not have acute lymphoblastic leukemia will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the presence of measurable residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) by comparing the standard method of flow cytometry with a novel approach using Raman spectroscopy. Flow cytometry, while commonly used, has limitations in sensitivity and standardization, prompting the exploration of Raman spectroscopy as a potential alternative. This technique utilizes the inelastic scattering of light to analyze the biochemical composition of biological samples, which may improve MRD detection. The study aims to determine if Raman spectroscopy can provide a more effective means of MRD evaluation in ALL patients.
Why it matters
Potential benefit: If successful, this study could lead to a more accurate and standardized method for MRD detection in leukemia patients, potentially improving prognosis and treatment outcomes.
How similar studies have gone: While flow cytometry is a well-established method, the use of Raman spectroscopy for MRD detection is novel and has not been widely tested in similar studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with ALL for whom MRD determination is clinically necessary will be included in the study. Exclusion Criteria: * Patients without ALL
Where it's running
-
Hospital Regional Alta Especialidad Bajio
León, Guanajuato, Mexico Recruiting
Study contacts
- Study coordinator: Lauro F Amador Medina, PhD
- Email: lafab2013@gmail.com
- Phone: 4772697907
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Observatory of adults with Ph+ ALL receiving BCR-ABL1 inhibitors with chemotherapy, steroids, or monoclonal antibodies
This study follows adults with Philadelphia-positive acute lymphoblastic leukemia who are being treated with a combination of BCR-ABL1 inhibitors and other therapies to see how they fare in real-world practice.
-
Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma
Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.
-
FXS0683 in relapsed or refractory blood cancers
This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.
-
CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers
This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.
-
TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults
This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.